By Pete Belden
July 07, 2017
Podcast

The rise of fully integrated third-party logistics (3PL) companies has transformed what once was a provider-based service into a strategic, consultative partnership — one that can help pharmaceutical companies ensure greater patient access and commercialization success. Pete Belden, President of ICS, speaks to PharmaVOICE about what it means to go beyond distribution and what it could mean for the future of pharmaceutical manufacturing.

Transcript

Welcome to the PharmaVOICE WebCast Network. 

In this episode, I meet with Pete Belden, president of ICS, an AmerisourceBergen company. We talk about the role of third-party logistics in the commercialization process, how manufacturers can solve challenges using 3PL partners, and where 3PL services are headed in the future.

I’m Dan Limbach, your host and producer of the PharmaVOICE WebCast Network.


Dan: Welcome to the podcast program, Pete. 

Pete: Thanks, Dan. Good to be here.

Dan: Pete, can you share with us the role that third-party logistics plays in the commercialization process and what manufacturers should expect from their 3PL partner? 

Pete: A third-party logistics business is one that provides outsource services for storage and distribution for pharmaceutical manufacturers. These products are typically not made to order. They’re made in batch quantities. So the manufacturer needs a way to store the excess finished goods and have it ready to ship immediately upon order, upon need from a patient. So a 3PL will receive those finished goods from the manufacturer, store those products in a controlled warehouse and fulfill those customer orders on their behalf.

Press play above to hear the entire podcast or click here to read the full transcript.